Literature DB >> 18042690

Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma.

G Kapatai1, P Murray.   

Abstract

Although the morphology of the pathognomonic Reed-Sternberg cells of Hodgkin lymphoma (HL) was described over a century ago, it was not until recently that their origin from B lymphocytes was recognised. The demonstration that a proportion of cases of HL harbour the Epstein-Barr virus (EBV) and that its genome is monoclonal in these tumours suggests that the virus contributes to the development of HL in some cases. This review summarises current knowledge of the pathogenesis of HL with particular emphasis on the association with EBV.

Entities:  

Mesh:

Year:  2007        PMID: 18042690      PMCID: PMC2095570          DOI: 10.1136/jcp.2007.050146

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  138 in total

1.  Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1).

Authors:  A G Eliopoulos; L S Young
Journal:  Oncogene       Date:  1998-04-02       Impact factor: 9.867

2.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals.

Authors:  R G Caldwell; J B Wilson; S J Anderson; R Longnecker
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

3.  EBV persistence in memory B cells in vivo.

Authors:  G J Babcock; L L Decker; M Volk; D A Thorley-Lawson
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

4.  Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis.

Authors:  A A Armstrong; F E Alexander; R Cartwright; B Angus; A S Krajewski; D H Wright; I Brown; F Lee; E Kane; R F Jarrett
Journal:  Leukemia       Date:  1998-08       Impact factor: 11.528

Review 5.  Hodgkin's disease: a disorder of dysregulated cellular cross-talk.

Authors:  A Pinto; V Gattei; V Zagonel; D Aldinucci; M Degan; A De Iuliis; F M Rossi; F Tassan Mazzocco; C Godeas; M Rupolo; D Poletto; A Gloghini; A Carbone; H J Gruss
Journal:  Biotherapy       Date:  1998

6.  Paediatric Hodgkin's disease in Spain: association with Epstein-Barr virus strains carrying latent membrane protein-1 oncogene deletions and high frequency of dual infections.

Authors:  A Santón; C Martín; A I Manzanal; M V Preciado; C Bellas
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

7.  Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.

Authors:  S P Lee; C M Constandinou; W A Thomas; D Croom-Carter; N W Blake; P G Murray; J Crocker; A B Rickinson
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

8.  Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.

Authors:  P G Murray; C M Constandinou; J Crocker; L S Young; R F Ambinder
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

Review 9.  Immune escape mechanisms in Hodgkin's disease.

Authors:  S Poppema; M Potters; L Visser; A M van den Berg
Journal:  Ann Oncol       Date:  1998       Impact factor: 32.976

10.  Lack of involvement of known oncogenic DNA viruses in Epstein-Barr virus-negative Hodgkin's disease.

Authors:  A A Armstrong; L Shield; A Gallagher; R F Jarrett
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

View more
  33 in total

Review 1.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Authors:  Hervé Ghesquières; Matthew J Maurer; Olivier Casasnovas; Stephen M Ansell; Beth R Larrabee; Eva Lech-Maranda; Anne J Novak; Anne-Laure Borrel; Susan L Slager; Pauline Brice; Cristine Allmer; Annie Brion; Steven C Ziesmer; Franck Morschhauser; Thomas M Habermann; Isabelle Gaillard; Brian K Link; Aspasia Stamatoullas; Christophe Fermé; Ahmet Dogan; William R Macon; Josée Audouin; James R Cerhan; Gilles Salles
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

3.  A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphoma.

Authors:  Ritu Lakhtakia; Ikram Burney
Journal:  Sultan Qaboos Univ Med J       Date:  2015-05-28

4.  Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.

Authors:  Angélica María Gamboa-Cedeño; Mariángeles Castillo; Wenming Xiao; Thomas A Waldmann; Stella Maris Ranuncolo
Journal:  J Cancer Res Clin Oncol       Date:  2019-04-02       Impact factor: 4.553

Review 5.  Adjuvants and lymphoma risk as part of the ASIA spectrum.

Authors:  Dana Butnaru; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 6.  Immune-based therapies for childhood cancer.

Authors:  Crystal L Mackall; Melinda S Merchant; Terry J Fry
Journal:  Nat Rev Clin Oncol       Date:  2014-10-28       Impact factor: 66.675

7.  Effects of lymphocyte profile on development of EBV-induced lymphoma subtypes in humanized mice.

Authors:  Eun Kyung Lee; Eun Hye Joo; Kyung-A Song; Bongkum Choi; Miyoung Kim; Seok-Hyung Kim; Sung Joo Kim; Myung-Soo Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

8.  Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo.

Authors:  Leah J Anderson; Richard Longnecker
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

Review 9.  The role of T cells in the microenvironment of Hodgkin lymphoma.

Authors:  Frederik Wein; Ralf Küppers
Journal:  J Leukoc Biol       Date:  2015-08-28       Impact factor: 4.962

10.  Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival.

Authors:  Stella M Ranuncolo; Stefania Pittaluga; Moses O Evbuomwan; Elaine S Jaffe; Brian A Lewis
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.